



Published in final edited form as:

Bone Marrow Transplant. 2013 November ; 48(12): 1554–1557. doi:10.1038/bmt.2013.100.

Outcomes of Hematopoietic Stem Cell Transplant Recipients with Rhinovirus Infection: A Matched, Case-Control Study

Foad I. Abandeh, M.B.B.S.¹, Mark Lustberg, M.D., Ph.D.¹, Steven Devine, M.D.², Pat Elder, M.A.², Leslie Andritsos, M.D.², and Stanley I. Martin, M.D.¹

¹Division of Infectious Diseases, The Ohio State University Wexner Medical Center, Columbus, OH, USA

²Division of Hematology, Bone Marrow Transplant Program, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Abstract

The impact of rhinovirus in hematopoietic stem cell transplant (HSCT) recipients is not well defined. A retrospective, matched, case-control study of HSCT recipients with rhinovirus was conducted between 2009 and 2011. Controls were matched for timing relative to transplant, malignancy, and stem cell source. There were 47 cases and 94 controls. Cases and controls did not differ with respect to age, gender, ethnicity, donor source, malignancy, conditioning regimen, immunosuppression, antimicrobial prophylaxis, or significant comorbidities. There were no differences in need for ICU care, 100 day mortality, hospice discharge, relapse of disease, GVHD or development of disease or infection due to CMV or EBV. Other infectious complications after rhinovirus diagnosis were also equal. However, there was an increased number of recurrent hospitalizations from any cause among cases (46.8% vs. 24.5%, $P=0.007$). Recurrent hospitalizations due to any infection were also more common in cases (34% vs. 14.9%, $P=0.015$). For patients who were diagnosed with rhinovirus pre-transplant ($n=13$), there was no difference in outcomes compared to matched controls. HSCT recipients with rhinovirus have an increased risk of hospital readmission. However, there was no difference in outcomes compared to matched controls. Transplantation in patients with active rhinovirus infection appears to be safe.

Keywords

Rhinovirus; hematopoietic stem cell transplant; respiratory virus

Introduction

Rhinovirus is a ubiquitous RNA virus known to cause the “common cold.” Infections occur throughout the year and are generally transmitted by aerosols or direct contact. Rhinovirus

Corresponding Author: Stanley I. Martin, M.D., Associate Professor, Clinical Internal Medicine, Division of Infectious Diseases, Transplant Infectious Diseases Service, The Ohio State University Wexner Medical Center, N1135 Doan Hall, 410 West 10th Ave., Columbus, OH 43210, Phone: 614-293-5666, FAX: 614-293-4556, stanley.martin@osumc.edu.

Conflicts of interest:
None

preferentially infects the upper airways and typically does not cause specific pathological changes. In symptomatic patients, the most common clinical manifestations include rhinorrhea, nasal obstruction, sneezing, sore throat, headache, malaise and fevers. Diagnosis of rhinovirus infectious disease is usually made on clinical grounds; however, viral culture, antigen detection, PCR and serologies may be used for diagnosis.¹ Treatment of rhinovirus infectious disease is mainly supportive due to the lack of agents targeting this virus.²

Viral respiratory infections in hematopoietic stem cell transplant (HSCT) recipients are a frequently encountered problem. Several studies have shown that rhinovirus can account for 25–40 % of cases.^{3,4} Although rhinovirus is known to cause mild upper respiratory tract infectious disease in immunocompetent hosts, it has been linked to fatal respiratory failure in immunosuppressed patients.^{5,6} These reports are limited, however, and the exact role or pathogenesis of rhinovirus in lower respiratory tract infectious disease has not been fully elucidated. In addition, around 13% of HSCT patients with rhinovirus infection may be completely asymptomatic and prolonged shedding of the virus in respiratory secretions is common.² Because of these concerns, some medical centers might postpone the HSCT procedure and implement infection control measures in infected patients. The aim of the present study is to evaluate the impact and clinical features of rhinovirus on this special patient population.

Patients and Methods

Study Population and settings

We conducted a retrospective, matched case-control study (1:2) ratio at The Ohio State University Wexner Medical Center (OSUWMC), a 976 bed tertiary medical center located in central Ohio. Using microbiological and demographic data from the HSCT program database, we identified all cases of rhinovirus isolated through PCR of the upper or lower respiratory tracts in patients who underwent HSCT from October 1, 2009 until October 31, 2011. If a patient had more than one HSCT or more than one positive sample for rhinovirus during the study period, then only the first transplant and first rhinovirus diagnosis that fit the inclusion criteria were used. The study was approved by the Institutional Review Board, protocol number 2011H0317.

Definitions and study design

Cases were defined as patients who underwent HSCT in the study period and had rhinovirus infection or disease anywhere from 30 days prior to transplant to any time after transplant. The controls were defined as patients who underwent HSCT in the same study period, and who were never diagnosed with rhinovirus, whether they had PCR testing of the upper or lower respiratory tracts or not. They were then matched according to year of transplant, timing relative to transplant, underlying malignancy, donor source (allogeneic vs. autologous), and for allogeneic HSCT recipients, source of stem cells (peripheral blood vs. umbilical cord blood). Patients under 18 years of age, prisoners and those who did not have documented follow-up after transplant were excluded from the study. Cases were followed for 100 days after rhinovirus diagnosis or 100 days after transplant, whichever was later. In

each of the controls, the time of follow-up was determined according to the time of rhinovirus diagnosis in the corresponding case.

The following data were collected after reviewing the patients' medical records: age, gender, ethnicity, underlying malignancy, type of HSCT, medical comorbidities, conditioning regimen, immunosuppression and anti-infective prophylaxis at time of rhinovirus diagnosis, laboratory findings at time of rhinovirus diagnosis (± 7 days), other infections after rhinovirus diagnosis, cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection or disease after transplant, in addition to outcomes at the end of the follow-up period including mortality, hospitalizations, and graft versus host disease (GVHD). For the cases, clinical features of rhinovirus infectious disease, timing of diagnosis and radiographic findings were also evaluated. GVHD was diagnosed clinically and confirmed histologically whenever possible by the HSCT team and graded according to the consensus criteria.⁷ Recurrent hospitalizations were defined as hospitalizations for any reason after rhinovirus diagnosis in the follow-up period.

Asymptomatic patients undergoing HSCT were not routinely screened for respiratory viral infections, and since all the patients with rhinovirus in our study had symptoms suggestive of upper or lower respiratory tract disease, we will use the term rhinovirus infectious disease to describe these patients. The term infection by itself should be limited to the detection of such viruses in the absence of signs or symptoms.²

Microbiology

Diagnosis of all rhinovirus cases from upper or lower respiratory samples was by the Luminex xTAG® respiratory viral panel polymerase chain reaction assay. This assay was universally implemented at OSUWMC at the beginning of the study period in October of 2009 and is widely used by our clinicians in patients who are undergoing or underwent HSCT and have upper or lower respiratory tract infection symptoms to guide approach to therapy. In addition to rhinovirus, this assay can be used to detect influenza, parainfluenza, adenovirus, and respiratory syncytial virus (RSV). Other infections were diagnosed on clinical grounds by the caring physicians by use of routine microbial cultures for bacterial and fungal infection as well as antigen and PCR-based assays for other viruses and fungal disease.

Statistical analysis

Patient characteristics and outcomes were compared between cases and controls using Fisher's exact test or a two sample t-test as appropriate unless otherwise specified. For multi-level categorical variables comparisons were made using chi-squares. In all analysis, a two-tailed P value of <0.05 was considered to be statistically significant. All data analysis was performed using Stata™ 10.1.

Results

There were 533 patients who underwent HSCT at the OSUWMC during the study period. Fifty-five patients were diagnosed with rhinovirus infectious disease. Of those, 47 cases were included in the study. Eight cases were excluded for the following reasons: prisoner

(n=1), lost to follow-up (n=1), could not be matched to controls (n=1) and diagnosis of rhinovirus >30 days prior to HSCT (n=5). There were no significant baseline differences in demographics between cases and controls (Table 1). Medical comorbidities, conditioning regimen, immunosuppressive and anti-infective agents were also similar.

Clinical features of rhinovirus infectious disease in HSCT

Table 2 lists the clinical features of rhinovirus infectious disease among the HSCT recipients. The average number of days for diagnosing rhinovirus infectious disease was 105.6 days post-transplant (median 72 days) and in the few cases prior to transplant (n=13), 11.1 days pre-transplant (median 7 days). All patients were symptomatic at the time of diagnosis. Most of the cases were initially diagnosed through a nasopharyngeal swab (93.6%) while three patients were diagnosed through a bronchoalveolar lavage (BAL) sample (one had upper and lower respiratory tract samples obtained simultaneously). Two of the three patients who underwent BAL died.

Outcomes

There were no significant outcome differences in need for ICU care, 100 day mortality or hospice discharge, relapse of disease, GVHD or development of disease or infection due to CMV or EBV (Table 3). Other infectious complications after rhinovirus diagnosis, including bacteremia, *C. difficile* enterocolitis, febrile neutropenia, pneumonia or other respiratory infections were also equivalent. However, overall there was a significantly increased number of recurrent hospitalizations from any cause in rhinovirus cases (46.8% vs. 24.5%, $P=0.007$). Recurrent hospitalizations due to an infectious cause were also significantly more common in the rhinovirus cases (34% vs. 14.9%, $P=0.015$). Of these, other upper and lower respiratory tract infectious disease were the cause of recurrent hospitalizations in seven cases and six controls ($P=0.125$). For patients who were diagnosed with rhinovirus infectious disease pre-transplant (n=13, mean of 11.1 days prior), there was no difference in outcomes compared to equivalent pre-transplant matched controls.

There was one case of RSV infectious disease after rhinovirus diagnosis among the cases, while there were seven parainfluenza virus infectious diseases among the controls. One of the control patients was admitted to an outside hospital and died the same day of admission. Information about that admission was not available for analysis.

Discussion

The role for rhinovirus in lower respiratory tract disease is not well established. There are several reports linking rhinovirus infection with croup, bronchiolitis, and chronic obstructive airway disease exacerbation in addition to bronchial asthma.⁸ Some reports suggest that rhinovirus might also be associated with lower respiratory tract disease in immunosuppressed HSCT recipients and be associated with poor outcomes. In one study, 275 patients who underwent conditioning chemotherapy in preparation for HSCT were identified as having an acute respiratory illness.⁵ Ninety-three patients (34%) had community respiratory viruses isolated, of which 22 were identified to be rhinoviruses. Seven of these cases were complicated by pneumonia, in which rhinovirus was also isolated

from a BAL specimen or an endotracheal aspirate in six. Two of these patients had an autopsy confirmed rhinovirus-associated interstitial pneumonia or ARDS.

In another study, BAL samples from 77 HSCT recipients with acute pulmonary infiltrates were tested for rhinovirus and coronavirus by PCR. Rhinovirus was detected in 6 patients. All but one patient died, however, a co-pathogen was detected in addition to rhinovirus in all of these patients and their mortality did not differ from patients who tested negative for rhinovirus in BAL samples.⁹ Two other cases of fatal lower respiratory tract infection in stem cell transplant recipients attributable to rhinovirus have been described.⁶ Both patients had asymptomatic shedding of rhinovirus before transplantation.

A retrospective study of 31 patients with upper or lower respiratory infections by rhinovirus and enterovirus in adult patients with hematological malignancies has also been described.¹⁰ Lower respiratory tract infection was present in 11 patients (7 enterovirus infections and 4 rhinovirus infections). Three patients with lower respiratory infections died. However, pulmonary co-pathogens were involved in all cases as well.

This is the first study comparing the outcomes of rhinovirus infectious disease on adult HSCT recipients with non-infected controls. We did not see any difference in terms of mortality, ICU care or other associated infections. The significant difference was mostly observed in the number of recurrent hospitalizations with rhinovirus cases admitted to the hospital more frequently after the rhinovirus diagnosis. This was true whether the readmission was for all cause hospitalization or due to a specific infectious event. Whether the rhinovirus itself increases susceptibility to infections, especially of the respiratory tract and thus admission rates, is difficult to determine. The other possible explanation of this finding is that HSCT patients with rhinovirus have more symptoms than non-infected controls and are therefore admitted more frequently.

There are several limitations to our study. It was retrospective and conducted at a single facility with a relatively small number of subjects. In addition, the PCR assay used may not always reliably distinguish between other picornaviruses (such as enteroviruses) and rhinoviruses. This means that it is at least possible that some of the cases included in the study as rhinovirus infections were actually secondary to enteroviruses or other closely related viruses. Given the ubiquity of rhinoviruses and their being the most common respiratory virus worldwide, it is safe to assume that the vast majority, if not all of our cases, were true rhinovirus infections.

Additional studies are needed to determine if transplanting patients with rhinovirus needs to be postponed. Current recommendations suggest that caregivers should consider deferring conditioning or chemotherapy for HSCT or leukemic patients with respiratory virus infections.² Although deferring such therapies may be better established in other respiratory virus infectious diseases, it is unclear if such an approach would be necessary in the case of rhinovirus infection. Distinguishing between actual infectious disease and infection may play a role in this determination. In this study, thirteen patients were diagnosed with rhinovirus pre-transplant. When comparing these patients to matched controls, there was no significant difference in mortality, ICU care or recurrent hospitalizations ($P=0.26$, 0.36 , and

0.35, respectively). Transplanting these patients appeared to be safe, but the small number of patients who were diagnosed pre-transplant has made these comparisons small.

In conclusion, this study demonstrates that HSCT patients with rhinovirus infectious disease do not have worse outcomes compared to matched controls. Larger prospective studies are needed to study the impact of rhinovirus infection and disease on this unique population, including specific determination of rhinovirus subtypes associated with severe disease, the incidence and effects of prolonged shedding, or association with other lower respiratory tract infections. Until then, in line with current recommendations regarding the prevention of these infections², continued infection control measures in HSCT patients with suspected respiratory viral infections should continue both in and out of the hospital setting.

Acknowledgments

None

References

1. Ronald, TB. Rhinovirus. In: Mandell, GL.; Bennett, JE.; Mandell, Dolin R.; Douglas; Bennett, editors. Principles and Practice of Infectious Diseases. 7th. Churchill livingstone; 2010. p. 2389-2398.
2. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. *Clin Infect Dis*. 2013; 56(2):258–66. [PubMed: 23024295]
3. Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. *Am J Med*. 1997; 102(3A):27–30. discussion 42–43. [PubMed: 10868139]
4. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. *Bone Marrow Transplant*. 2003; 32(1):73–77. [PubMed: 12815481]
5. Ghosh S, Champlin R, Couch R, Englund J, Raad I, Malik S, et al. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. *Clin Infect Dis*. 1999; 29(3):528–532. [PubMed: 10530441]
6. Gutman JA, Peck AJ, Kuypers J, Boeckh M. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. *Bone Marrow Transplant*. 2007; 40(8):809–811. [PubMed: 17704788]
7. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. *Bone Marrow Transplant*. 1995; 15(6):825–828. [PubMed: 7581076]
8. Hayden FG. Rhinovirus and the lower respiratory tract. *Rev Med Virol*. 2004; 4(11):17–31. [PubMed: 14716689]
9. Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. *Clin Infect Dis*. 2003; 36(9):1139–1143. [PubMed: 12715308]
10. Parody R, Rabella N, Martino R, Otequi M, del Cuerdo M, Coll P, et al. Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies. *Am J Hematol*. 2007; 82(9):807–811. [PubMed: 17563077]

Table 1

Patient characteristics comparing cases and controls

	Cases (n=47)	Controls (n=94)	P value
Age ^I (Median with range)	54 (range 21–73, 25–75% range 34–61)	54 (range 20–74, 25–75% range 46–61)	0.19
Male Gender	57.5% (27)	61.7% (58)	0.63
Race/Ethnicity			
Caucasian	83.0% (39)	88.3% (83)	0.46
African-American	6.4% (3)	6.4% (6)	
Other	10.6% (5)	5.3% (5)	
Type of transplant			
Allogeneic – Related	21.2% (10)	19.2% (18)	0.99
Allogeneic – Unrelated	27.7% (13)	29.8% (28)	
Allogeneic – Umbilical Cord	6.4% (3)	6.4% (6)	
Autologous	44.7% (21)	44.7% (42)	
Underlying Malignancy			
NHL	36.2% (17)	36.2% (34)	
AML	25.5% (12)	25.5% (24)	
MM/Amyloid	23.4% (11)	23.4% (22)	
ALL	4.3% (2)	4.3% (4)	
CLL	4.3% (2)	4.3% (4)	
CML	2.1% (1)	2.1% (2)	
HD	2.1% (1)	2.1% (2)	
MDS	2.1% (1)	2.1% (2)	
Medical co-morbidities			
DM	10.6% (5)	12.8% (12)	0.72
HTN	31.9% (15)	37.2% (35)	0.53
COPD/Asthma	17.0% (8)	8.5% (8)	0.13
CAD	2.1% (1)	7.5% (7)	0.20
CHF	12.8% (6)	3.2% (3)	0.03
CKD/ESRD	6.4% (3)	5.3% (5)	0.80
Prior HSCT	6.4% (3)	6.4% (6)	1.0
Hypothyroidism	8.5% (4)	6.4% (6)	0.64
OSA	10.6% (5)	5.3% (5)	0.25
DVT/PE	17.0% (8)	10.6% (10)	0.28
Conditioning regimen			
Ablative	54.4% (25)	51.6% (48)	0.76
Non-myeloablative	45.6% (21)	48.4% (45)	
Immunosuppressive therapy			
Tacrolimus	27.7% (13)	28.7% (27)	0.90

	Cases (n=47)	Controls (n=94)	P value
Corticosteroids	25.5% (12)	16% (15)	0.17
Mycophenolate	12.8% (6)	4.3% (4)	0.06
Sirolimus	2.1% (1)	2.1% (2)	1.0
Cyclosporine	0% (0)	1.1% (1)	0.48
Anti-infective prophylaxis			
<i>Pneumocystis</i>	27.7% (13)	33.0% (31)	0.52
Fungi	50.0% (23)	41.5% (39)	0.34
Herpesvirus	70.2% (33)	73.4% (69)	0.60
Bacteria	8.5% (4)	5.3% (5)	0.47
Laboratory values			
WBC (Mean \pm SD)	6.5 \pm 7.7	5.1 \pm 3.5	0.16
ANC (Mean \pm SD)	4.1 \pm 4.1	3.3 \pm 2.5	0.17
Cr (Mean \pm SD)	1.1 \pm 0.7	1.0 \pm 0.5	0.14
ALT (Mean \pm SD)	45.3 \pm 9.7	44.7 \pm 7.9	0.96

NHL=Non-Hodgkin lymphoma, AML=Acute myelogenous leukemia, MM=Multiple myeloma, ALL=Acute lymphocytic leukemia, CLL=Chronic lymphocytic leukemia, CM=Chronic myelogenous leukemia, HD=Hodgkin disease, MDS=Myelodysplasia, DM=Diabetes mellitus, HTN=Hypertension, COPD=Chronic obstructive pulmonary disease, CAD=Coronary artery disease, CHF=Congestive heart failure, CKD=Chronic kidney disease, ESRD=End-stage renal disease, HSCT= hematopoietic Stem cell transplant, OSA=Obstructive sleep apnea, DVT=Deep venous thrombosis, PE=Pulmonary embolism, WBC=White blood cells, SD=Standard deviation, ANC=Absolute neutrophil count, Cr=Creatinine, ALT=Alanine aminotransferase

¹ Median values were felt to be a better measure of central tendency for age and so the Wilcoxon rank-sum test was used to generate a *P*-value. Other continuous variables in the table were analyzed using two sample *t*-tests.

Table 2

Clinical manifestations, radiographic features, timing and source of rhinovirus infectious disease in HSCT recipients

Characteristic	Frequency (n)
Signs and symptoms	
Cough	78.8% (37)
Fever	36.1% (17)
Congestion	31.9% (15)
Dyspnea	23.4% (11)
Rhinorrhea	20.0% (14)
Sore throat	17.0% (8)
Chest pain	8.5% (4)
Myalgia	6.4% (3)
Headache	6.4% (3)
Chest X-ray radiograph findings (N=43)	
Clear	58.1% (25)
Atelectasis	16.3% (7)
Unilateral infiltrate	14.0% (6)
Bilateral infiltrate	11.6% (5)
Chest X-ray or chest CT findings with any infiltrate	31.9% (15)
Sinus CT with evidence of sinusitis	8.5% (4)
Source of diagnosis	
Nasopharynx	93.6% (44)
BAL	4.3% (2)
Both	2.1% (1)
Time period of diagnosis	
December – February	12.8% (6)
March – May	30.0% (14)
June – August	25.5% (12)
September – November	31.9% (15)
Inpatient at diagnosis	66.0% (31)

HSCT= hematopoietic Stem cell transplant, CT=Computed tomography scan, BAL=Bronchoalveolar lavage

Table 3

Outcomes of HSCT patients with rhinovirus infectious disease and matched controls

	Cases (n=47)	Controls (n=94)	P-value
Death or hospice discharge	17.0% (8)	14.9% (14)	0.74
Relapse of malignancy	17.0% (8)	19.2% (18)	0.76
Recurrent hospitalization	46.8% (22)	24.5% (23)	0.007
Recurrent hospitalization from infection	34.0% (16)	14.9% (14)	0.015
Number of recurrent hospitalizations in those rehospitalized	1.4 ± 0.6	1.8 ± 0.9	0.06
ICU admissions and/or mechanical ventilation	10.6% (5)	12.8% (12)	0.72
Other infectious syndromes			
Pneumonia	25.5% (12)	13.8% (13)	0.09
Neutropenic fever	12.8% (6)	6.4% (6)	0.20
<i>C. difficile</i>	6.4% (3)	5.3% (5)	1.0
Other URID	17.0% (8)	17.0% (16)	1.0
Bacteremia	23.4% (11)	10.6% (10)	0.076
CMV viremia	12.8% (6)	20.2% (19)	0.35
EBV viremia	2.1% (1)	4.3% (4)	0.67
GVHD			
Any GVHD	73.1% (19)	61.5% (32)	0.45
Skin GVHD	50.0% (13)	44.2% (23)	0.64
Liver GVHD	15.4% (4)	13.5% (7)	1.0
Other GVHD	3.9% (1)	9.6% (5)	0.66

HSCT= hematopoietic Stem cell transplant, ICU=Intensive care unit, URID=Upper respiratory tract infectious disease, CMV=Cytomegalovirus, EBV=Epstein-Barr virus, GVHD=Graft vs. host disease